As of June 17, 2025, Chromadex Corp (CDXC) reports a ROA (Return on Assets) of 12.52%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Chromadex Corp's ROA (Return on Assets)
Over recent years, Chromadex Corp's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | 12.52% |
| 2023-12-31 | -8.98% |
| 2022-12-31 | -30.60% |
| 2021-12-31 | -46.91% |
| 2020-12-31 | -51.96% |
This slight upward trend highlights how Chromadex Corp manages its efficiency in using assets to generate earnings over time.
Comparing Chromadex Corp's ROA (Return on Assets) to Peers
To better understand Chromadex Corp's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Chromadex Corp (CDXC) | 12.52% |
| Medpace Holdings Inc (MEDP) | 19.25% |
| Ergomed PLC (ERGO.L) | 11.58% |
| Genovis AB (GENO.ST) | 10.05% |
| Innovotech Inc (IOT.V) | 6.98% |
| IQVIA Holdings Inc (IQV) | 5.10% |
Compared to its competitors, Chromadex Corp's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.